Ophthalmic ultrasound and laser device maker Quantel Medical (Clermont-Ferrand, France) has received FDA approval for its Solutis glaucoma laser. The approval follows the expiration of a patent issued to Massachusetts General Hospital (Boston, MA), which restricted the company and several other laser manufacturers from marketing selective laser trabeculoplasty (SLT) technology within the U.S. The company has been providing SLT technology to customers outside the U.S. since 2007.
SLT is a first-line and adjunct therapy option for reducing intraocular pressure (IOP) in glaucoma patients. The noninvasive procedure delivers targeted laser energy, inducing a regenerative response at the cellular level. Due to the laser energyâs gentle application, the treatment is repeatable and not associated with the ocular and systemic side effects or compliance issues commonly linked to glaucoma drugs.
The Solutis laser's design is adaptable to a physician's current slit lamp, eliminating the need for dedicated space and lowering end-user cost. It is also transportable from room to room or office to office, and includes storage accessories when not in use.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!